Taxotere Will Benefit From “Average Sales Price” Reimbursement
Executive Summary
Aventis expects Taxotere's performance in the U.S. to receive a boost from the implementation of "average sales price" reimbursement under Medicare in 2005
You may also be interested in...
Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?
Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid
Aventis Defense Against Sanofi: Strong Pipeline Or Irrational “Exubera-nce”?
Aventis is using the prospects of Genasense as its first line of defense against Sanofi's hostile takeover bid
J&J Procrit Medicare Reimbursement Will Be 87% Of AWP Under Final Rule
Johnson & Johnson's Procrit will be reimbursed at 87% of average wholesale price under Medicare Part B in 2004, two percentage points higher than most drugs